Drug news
Spectrum Pharma acquires world rights to Zevalin for NHL
Spectrum Pharmaceuticals will acquire from Bayer Healthcare the licensing rights to market Zevalin (ibritumomab tiuxetan) injection for intravenous use for the non-Hodgkin's lymphoma treatment outside the USA. Spectrum already has the rights to market the drug in the USA and will now hold the worldwide rights to Zevalin. The product is currently approved in more than 40 countries outside the US (covering Europe, Latin America and Asia) for the treatment of follicular B-cell non-Hodgkin's lymphoma. Bayer wish to move away from haematological oncology.